Phase 2 obesity trial, 2023
Jastreboff and colleagues reported in the NEJM that 338 adults on retatrutide lost up to 24.2 percent of body weight at 48 weeks against 2.1 percent on placebo.
SourceBack to search
Weight LossMetabolic
Retatrutide
Retatrutide is an investigational triple agonist acting at the GLP-1, GIP and glucagon receptors, developed by Eli Lilly for obesity and metabolic disease. It is not approved by any regulator and is legally available only through its clinical trial programme.
- Lowest cost / mg
- $1.42/mg
- at ZC Labs
- Vendors listed
- 68
- In stock
- 259 of 262
- listings
- COA reports
- 208
Vendor listings
Compare Retatrutide prices.
Show prices as
49 listings · Retatrutide · 20mg
- Renova PeptidesLowest $/mg
In stock20mgseen 6d ago
In stock20mgseen 6d ago
In stock20mgseen 7d ago
In stock20mgseen 5d ago
In stock20mgseen 5d ago
In stock20mgseen 4d ago
In stock20mgseen 7d ago
In stock20mgseen 3d ago
In stock20mgseen 4d ago
In stock20mgseen 4d ago
In stock20mgseen 6d ago
In stock20mgseen 4d ago
In stock20mgseen 6d ago
In stock20mgseen 3d ago
In stock20mgseen 4d ago
In stock20mgseen 4d ago
In stock20mgseen 7d ago
In stock20mgseen 4d ago
In stock20mgseen 4d ago
In stock20mgseen 3d ago
Overview
What is Retatrutide?
Retatrutide is an investigational triple agonist acting at the GLP-1, GIP and glucagon receptors, developed by Eli Lilly for obesity and metabolic disease. It is not approved by any regulator and is legally available only through its clinical trial programme.
- Weight Management
- Appetite Control
- Metabolic Health
- Liver Fat
What the research reports
Reported benefits of Retatrutide
Outcomes described across the published Retatrutide literature and ongoing study. Read each as research context, not a promised result.
- 01
Large weight loss in trials
Phase 2 work reported dose dependent weight loss up to 24.2 percent at 48 weeks against 2.1 percent on placebo in adults with obesity. Reported in research settings.
- 02
Triple receptor activation
Activates GLP-1 for appetite control, GIP for metabolic efficiency and glucagon for energy expenditure simultaneously, a broader reach than dual agonists.
- 03
Glycaemic control research
Phase 2 trials in type 2 diabetes reported HbA1c reductions up to 2.02 percent alongside meaningful reductions in body weight. Reported in research settings.
- 04
Liver fat reduction study
A phase 2a trial in 98 patients with fatty liver disease reported liver fat down up to 82.4 percent at 24 weeks, with 86 percent reaching normal liver fat.
- 05
Body composition change data
A 2025 analysis reported total body fat mass reduced by 15 to 26 percent against placebo in people with type 2 diabetes. Reported in research settings.
Dosage and protocol
Retatrutide dosage and protocol
Trial protocols titrate from 1 mg weekly through 2, 4 and 8 mg to a 12 mg target, escalating every four weeks. The half-life is approximately six days at steady state dosing.
- Route
- Subcutaneous injection
- Example range
- 1-12 mg
- Frequency
- Once weekly
- Timing
- Once weekly, same day. Escalate every four weeks to limit nausea.
Clinical evidence
Clinical evidence for Retatrutide
The published record for Retatrutide, labeled by strength so you can see what is settled and what is emerging.
Type 2 diabetes trial, 2023
A Lancet phase 2 trial in 281 people with type 2 diabetes reported HbA1c improved by up to 2.02 percent with body weight down by as much as 16.94 percent. Reported in the cited paper.
SourceLiver disease phase 2a study
A 2024 Nature Medicine trial in 98 patients reported liver fat down up to 82.4 percent at 24 weeks, with 86 percent reaching normal liver fat content. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Semaglutide
- Overlapping GLP-1 activity. Combining raises gastrointestinal burden with no established added benefit.
- Tirzepatide
- Overlapping GLP-1 and GIP activity. The two are not combined in any clinical protocol. Confidence: emerging.
- Insulin therapy
- Glucose lowering effects stack, so hypoglycaemia risk rises when incretin therapy is added to insulin.
- Sulfonylureas
- Added glucose lowering raises hypoglycaemia risk and usually calls for a dose review by a clinician.
Questions
Frequently asked questions.
What is Retatrutide?
Retatrutide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Retatrutide?
Retatrutide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Retatrutide work?
Like other research peptides, Retatrutide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Retatrutide for research use only?
Yes, products like Retatrutide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Retatrutide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
